The Beacon trial enrolled 31 patients, randomizing them at a rate of 3:2:2 to receive a daily 45-mg oral dose of brepocitinib ...
Roivant Sciences ROIV stock surged on Friday on positive Phase 2 results for brepocitinib in cutaneous sarcoidosis (CS), an ...
In a small trial, Roivant's immune drug significantly outperformed placebo in clearing lesions caused by a rare skin disease.
Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 ...
According to Priovant, the Phase 2 BEACON study is the first industry-sponsored placebo-controlled trial in cutaneous sarcoidosis to deliver positive data.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results